Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 12/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 11/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27096010 | 0.86 | CCNT1 (0.40) | CCNT1AXLCDK9CHEK1 | |
| SCHEMBL27096016 | 0.84 | CCNT1 (0.45) | CCNT1AXLCDK9JAK2JAK3 | |
| SCHEMBL27095975 | 0.82 | CCNT1 (0.38) | CCNT1AXLCDK9CHEK1 | |
| SCHEMBL27095944 | 0.81 | CCNT1 (0.47) | CCNT1AXLCDK9 | |
| SCHEMBL27095908 | 0.80 | UTS2R (0.44) | CCNT1CDK9JAK2JAK3CCND3 | |
| SCHEMBL27095897 | 0.80 | CHEK1 (0.43) | CCNT1AXLCDK9JAK2CHEK1 | |
| SCHEMBL27096031 | 0.80 | CCNT1 (0.42) | CCNT1CDK9ROCK2CCND3CDK6 | |
| SCHEMBL27095816 | 0.79 | HDAC6 (0.45) | CCNT1AXLCDK9CHEK1 | |
| SCHEMBL27096001 | 0.79 | CCNT1 (0.42) | CCNT1AXLCDK9CHEK1 | |
| SCHEMBL24493550 | 0.78 | MRGPRX1 (0.44) | CCNT1AXLCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | SERPINB1, XDH, ACE | CCNT1 644/4885AXL 4214/4885CDK9 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.